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Abstract: Behcet’s disease (BD) is a multisystemic disorder of
unknown etiology characterized by relapsing oral–genital ulcers, uvei-
tis, and involvement of vascular, gastrointestinal, neurological, and
musculoskeletal system. Although disease pathogenesis is still unclear,
both innate and adaptive immunity have shown to play a pivotal role,
and multiple proinflammatory cytokines seem to be involved in different
pathogenic pathways that eventually lead to tissue damage.
The aims of our study were to evaluate serum cytokines levels of IL-
8, IL-18, IFN-a2a, IL-6, IFN-g, CXCL10, CXCL11, CXCL9, and SAA
levels in patients with BD, in comparison to healthy controls (HC), and
to correlate their levels to disease activity.
We included 78 serum samples obtained from 58 BD patients and
analyzed a set of proinflammatory cytokines including IL-8, IL-18,
IFN-a2a, IL-6, IFN-g, CXCL10, CXCL11, and CXCL9 by multiplex
bead analysis as well as SAA by enzyme-linked immunosorbent
assay.
Compared to HC, BD patients showed elevated cytokine levels
of IL-8, IL-18, IFN-a2a, and IL-6, and low levels of CXCL11. BD
patients with SAA serum levels >20 mg/L showed higher levels of
proinflammatory markers than HC or group with SAA20 mg/L. IL-
18, IFN-a2a, and IL-6 were higher in BD group with SAA>20 mg/L
than HC, while IL-8 and CXCL9 levels were higher than in patients
with SAA 20 mg/L and HC.
Active BD patients with SAA >20 mg/L exhibited elevatedlco, PhD, Mauro G PhD,
MD, PhD, and Florenzo Iannone, MD, PhD
(Medicine 94(42):e1858)
Abbreviations: APC = antigen-presenting cell, BD = Behcet’s
disease, HC = healthy controls, PBMC = peripheral blood
mononuclear cell, SAA = serum amyloid-A.
INTRODUCTION
B ehcet’s disease (BD) is a chronic systemic inflammatorysyndrome at the crossroad between autoimmune and auto-
inflammatory diseases.1 Beside the classical symptoms
represented by muco-cutaneous lesions and chronic relapsing
bilateral uveitis, vascular, gastro-enteric, neurological, and joint
involvement may also occur.2 Although disease pathogenesis is
still unclear, both innate and adaptive immunity have shown to
play a pivotal role.3–5 The recent understandings on cellular and
molecular biology seem to suggest that an imbalance of the Th1/
Th2 polarization in favor of Th1 would be able to generate an
inflammatory process leading to a CD4þ T lymphocytes clonal
expansion, producing high concentrations of both proinflam-
matory cytokines (such as IFN-g, IL-6, and IL-8) and cytotoxic
CD8þ cells. Moreover, enhanced circulating Th17 lympho-
cytes as well as increased levels of IL-17A have also been
reported in BD.6 In addition, high levels of the classical Th1
type cytokine IFN-g have been found in patients with ocular
involvement.7 Similarly, IFN-g secretion is stimulated by
natural killer cells through IL-18 action closely relating to
BD disease activity and local inflammatory response.8 Also,
IFN-g leads to IFN-g-inducible CXCR3 ligands production
(including CXCL9, CXCL10, and CXCL11), known to be
involved in various angiogenesis-related disease as well as
immunological disorders by inducing the recruitment of acti-
vated Th1 cells.9 In this regard, few data are available on the
role of these chemokines in BD pathogenesis with the exception
of CXCL10 chemokine, known to be involved in inducing
inflammation in nervous system of BD patients.10–16 Not least
in importance is the action of antigen-presenting cells (APCs),
leading to inflammatory T-cell response as well as neutrophils
activation which through the secretion of IL-18, IL-1, IL-6, IL-
8, and TNF-a.6,13,16,17
To date, there are no specific laboratory clues to assess
disease activity.18 In this regard, the acute phase protein serum
amyloid-A (SAA), synthesized by the liver under the stimulus
of proinflammatory cytokines such as IL-6, has been investi-
gated as a potential laboratory marker for several rheumatologic
disorders.19
Recently the role of SAA levels as a potential marker of
disease activity in BD patients has been explored, and it hasccurrence of oral aphthosis, neurological
significantly associated with high serum
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TABLE 1. Demographic, Laboratory, and General Clinical
Characteristics of Patients Affected by Behcet’s Disease
Recruited in Our Study
BD Patients
(n¼ 58)
BD Serum
Samples (n¼ 78)
Males n, % 28 (48) 35 (45)
Females n, % 30 (52) 43 (55)
Disease onset
(mean SD)
in years
31.43 12.94 31.37 13.37
Disease duration
(mean SD)
in years
12.74 9.31 13.81 9.94
HLA-B51
positivity, n, %
34 (59) 50 (64)
Serum amyloid-A
levels meanSD
(range mg/L)
71.91 135.06
(793.40–4.78)
110.08 227.55
(1518.40–1.80)
Clinical features, %
Uveitis 18/58 (31) 26/78 (33)
Oral aphthosis 23/58 (40) 34/78 (44)
Genital aphthosis 7/58 (12) 9/78 (12)
Cutaneous disease 17/58 (29) 20/78 (26)
Central nervous
system
involvement
6/58 (10) 8/78 (10)
Vascular
involvement
3/58 (5) 4/78 (5)
Gastrointestinal
involvement
14/58 (24) 17/78 (22)
BD¼Behcet’s disease, HLA¼ human leukocyte antigen, SD¼ stan-
Medicine  Volume 94, Number 42, October 2015Therefore, the present study was aimed at investigating any
potential correlation among cytokines profile, serum levels of
SAA, and disease activity in BD patients.
MATERIALS AND METHODS
Patients
Seventy-eight serum samples were routinely collected
from 58 BD patients (28 males, 30 females, mean age
44.7 12.2 years) who met the International Study Group
classification criteria for BD;21 the samples were collected
every 3 to 4 months and in case of disease relapse.
Of these, 37 samples were obtained from patients with
active disease and 41 from patients with inactive disease.
The primary aim of the study was to compare cytokines
profile among patients with active BD, patients with inactive
BD and healthy controls (HC); the secondary aims were to
evaluate the levels of SAA according to BD activity; explore
any potential correlation among levels of cytokines, SAA, and
status of disease activity.
Patients were included in the active-BD group if they had at
least 2 of the following BD-related clinical findings: uveitis, oral
aphthosis, genital aphthosis, cutaneous disease, central nervous
system involvement, vascular involvement, and gastrointestinal
involvement. Samples were also obtained from 32 HC (6 males,
26 females, mean age 41 8.3 years). Table 1 summarizes the
clinical and demographic characteristics of BD patients.
The endpoints of the study were: to determine serum levels
of IL-8, IL-18, IFN-a2a, IL-6, IFN-g, CXCL10, CXCL11,
CXCL9, and SAA serum concentration every 3 to 4 months
and in case of disease relapse; to correlate IL-8, IL-18, IFN-a2a,
IL-6, IFN-g, CXCL10, CXCL11, CXCL9, and SAA serum
concentration with the status of disease activity.
Written informed consent was obtained both from patients
and HC. The study protocol was reviewed and approved by the
Ethical Committee of the Medical University of Bari. Demo-
graphic and clinical information was obtained through struc-
tured interview, review of medical records, physical
examination, and laboratory tests.
Multiplex Bead Analysis
Serum cytokine levels of IL-8, IL-18, IFN-a2a, IL-6, IFN-
g, CXCL10, CXCL11, and CXCL9 were determined, using a
Bio-Rad cytokine bead arrays according to the manufacturers’
instructions. Data analysis was performed using the Bioplex
manager software 6.0 and results displayed as meanSD.
SAA Enzyme-Linked Immunosorbent Assay
SAA serum concentration was determined with a com-
mercial solid phase sandwich enzyme-linked immunosorbent
assay (Human SAA, BioSource Europe S.A., Belgium) accord-
ing to the manufacturer’s protocol. Although literature data
suggest that SAA levels are elevated over the threshold of
10 mg/L,22 we referred in our analysis to a cut-off of 20 mg/
L, since it represents the threshold of our laboratory.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
5 software. Results were expressed as mean standard devi-
ation. Analysis of variance was used to analyze differences
Lopalco et albetween groups. Two-tailed Mann–Whitney U test (for 2
nonparametric groups) and Student’s t-test (for 2 parametric
groups) were used for statistical comparisons between groups.
2 | www.md-journal.comSignificance was defined as P< 0.05. Correlations were calcu-
lated using Spearman correlation (2-tailed P-value) as well as
Pearson correlation test when required.
RESULTS
The characteristics of 78 serum samples obtained from 58
BD patients are summarized in Table 1. Specifically, 37/78
(47%) were collected from patients with active disease; more-
over, 69/78 were treated at the time of serum collection. Anti-
TNF as monotherapy (13/78, 17%) or in combination with
disease-modifying antirheumatic drugs (16/78, 21%) and dis-
ease-modifying antirheumatic drugs monotherapy (26/78, 33%)
were the commonest treatments at the time of serum collection.
Table 2 summarizes the treatment at the time of serum
collection.
Cytokine levels of IL-8, IL-18, IFN-a2a, IL-6, IFN-g,
CXCL10, CXCL11, and CXCL9 were analyzed in 78 serum
samples from BD patients and 32 HC. In BD patients serum
concentrations of IL-8 (P¼ 0.0001), IL-18 (P¼ 0.0058), IFN-
a2a (P¼ 0.0181), and IL-6 (P¼ 0.0233) were significantly
higher than in HC. Conversely, CXCL11 resulted lower in BD
than in HC (P¼ 0.0369), while no differences in CXCL10 and
standard deviation.CXCL9 levels between BD and HC were found (Figure 1,
Table 3). Detectable levels of IFN-g were found in few samples
both in HC and BD subjects, for this reason this cytokine was not
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. BD Patients’ Therapy at the Time of Serum
Collection
Treatments N, %
DMARDs 26/78 (33)
Anti-TNF 13/78 (17)
DMARDsþ anti-TNF 16/78 (21)
Anakinra 7/78 (9)
Canakinumab 1/78 (1)
Tocilizumab 1/78 (1)
Chorticosteroid 5/78 (6)
No treatment 9/78 (12)
BD¼Behcet’s disease, DMARD¼ disease-modifying antirheumatic
Medicine  Volume 94, Number 42, October 2015included in the analysis. In addition statistical analysis by Spear-
man rho test showed significant correlations between serum
concentration of IL-8 and IL-18 (r¼ 0.337, P¼ 0.002), IL-6
(r¼ 0.333, P¼ 0.004) serum levels, and strong correlation was
found between IL-8 and IFN-a2a (r¼ 0.661, P< 0.0001). More-
over, also IL-6 serum levels positively correlated with IFN-a2a
(r¼ 0.356, P¼ 0.0011) serum concentrations. In order to under-
stand whether disease activity may affect cytokine profiles, we
compared serum cytokines levels between active-BD (n¼ 37),
inactive-BD (n¼ 41), and HC (n¼ 32) subjects. IL-8 and IL-18
resulted higher in both active-BD (P¼ 0.0001 and 0.012, respect-
ively) and inactive-BD (P¼ 0.0001 and 0.0128, respectively)
drug, TNF¼ tumor necrosis factor.than in HC. No differences were observed in serum levels of
CXCL10 and CXCL9 between patients and HC. Interestingly
IFN-a2a (P¼ 0.0141) and IL-6 (P¼ 0.0332) serum levels were
FIGURE 1. Serum cytokines levels in BD patients and HC. Circulating
were analyzed in serum samples obtained from BD patients (n¼78) and
test and Student’s t-test were carried out to check for statistical significa
significant). BD¼Behcet’s disease, HC¼healthy controls, SD¼ stand
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.significantly higher in active-BD than HC. Moreover, CXCL11
serum concentration was significantly lower in inactive-BD than
HC (P¼ 0.0154) (Figure 2, Table 3).
When cytokines were evaluated in the active-BD group,
serum IL-8 concentration positively correlated with IL-18
(r¼ 0.381, P¼ 0.02) and a strong correlation was found with
IFN-a2a (r¼ 0.737, P< 0.0001) serum levels. In addition, IFN-
a2a serum concentration also correlated positively with serum
concentration of IL-6 (r¼ 0.513, P¼ 0.007).
When IL-8, IL-18, IFN-a2a, and IL-6 serum levels were
compare between BD patients with SAA serum levels 20 mg/
L (n¼ 20), >20 mg/L (n¼ 50) and HC (n¼ 32), patients with
SAA levels below 20 mg/L showed significantly increased IL-8
(P¼ 0.002), IFN-a2a (P¼ 0.0213) and significantly decreased
CXCL10 (P¼ 0.0205) and CXCL11 (P¼ 0.0004) serum levels
compared to HC. Interestingly, no differences were observed in
IL-18, IL-6, and CXCL9 serum levels between patients with
SAA below 20 mg/L and HC. Patients with SAA >20 mg/L
showed serum IL-8 levels significantly higher than patients with
SAA 20 mg/L (P¼ 0.0298) and HC (P¼ 0.0001). Serum IL-
18 (P¼ 0.0044), IFN-a2a (P¼ 0.0212), and IL-6 (P¼ 0.0042)
levels were significantly higher than in HC, but comparable to
BD subjects with SAA 20 mg/L. In addition, CXCL9 resulted
higher when SAA was higher than 20 mg/L compared to HC
(P¼ 0.032) and patients with serum levels 20 mg/L
(P¼ 0.0242). Furthermore, we observed that CXCL10 and
CXCL11 serum levels showed to be significantly higher when
SAA levels were >20 mg/L than in patients with lower SAA
levels (P¼ 0.0239 and 0.0123, respectively), but were compar-
able to HC group (Figure 3, Table 3).
Finally, we found SAA serum levels positively correlated
Cytokines and Behcet’s Diseasewith IL-8 (r¼ 0.273, P¼ 0.022), IL-6 (r¼ 0.421, P¼ 0.0005),
CXCL10 (r¼ 0.293, P¼ 0.014), CXCL11 (r¼ 0.318, P¼
0.007), and CXCL9 (r¼ 0.336, P¼ 0.006) serum levels.
level of IL-8, IL-18, IL-6, IFN-a2a, CXCL11, CXCL10, and CXCL9
HC (n¼32). Data are expressed as mean SD. Mann–WhitneyU
nce between groups (

P<0.05,

P<0.01,

P<0.01, ns¼not
ard deviation.
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TABLE 3. Levels of Cytokines in HC and BD Patients
HC BD Inactive-BD Active-BD Low-SAA High-SAA
IL-8, pg/mL 6.18 3.36 14.84 15.67 14.48 17.47 15.24 13.64 9.853 4.74 18.11 18.56,,
IL-18, pg/mL 65.59 42.91 92.97 45.92 94.65 51.17 91.1 39.92 90.19 52.84 94.47 43.88
IFN-a-2a, pg/mL 28.33 14.59 37.77 16.35 35.99 16.44 39.56 16.39 40.46 11.68 38.72 17.74
IL-6, pg/mL 2.01 1.69 3.77 4.11 3.32 2.90 4.208 5.01 2.124 1.24 4.499 4.70
CXCL10, pg/mL 188.85 89.47 179.3 133.6 166.3 129.5 193.6 138.4 143.6 134.9 201.2 135.2
CXCL11, pg/mL 31.52 17.11 25.34 21.07 22.56 19.25 28.42 22.78 15.67 12.36 30.44 23.32
CXCL9, pg/mL 263.52 130.70 338.1 238.2 320.8 260.8 356.5 213.8 240 122 388 261.9,
Data are expressed as meanSD. Mann–Whitney U test and Student’s t-test were carried out to check for statistical significance between
et’s

gr
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Our study was aimed at exploring any potential correlation
among cytokines profile, serum levels of SAA and disease
activity in BD patients. First of all, we analyzed serum
levels of a core set of cytokines (IL-8, IL-18, IFN-a2a, IL-6,
IFN-g, CXCL10, CXCL11, and CXCL9) and SAA serum
concentration.
BD is a complex inflammatory disorder characterized by an
abnormal innate and adaptive immune response leading to hyper-
activation of proinflammatory mediators. In the present study, in
line with previously reported data,11,23,24 we found elevated
levels of several inflammatory markers in BD patients compared
groups. Significance between groups versus the HC group. BD¼Behc
P< 0.01,

P< 0.001,

P< 0.05 between low- versus high-SAAto HC. In particular, BD appears associated to high levels of IL-8,
IL-18, IL-6, and IFN-a especially in patients with high disease
activity and SAA serum levels higher than 20 mg/L.
FIGURE 2. Serum cytokines levels in inactive-BD, active-BD, patients
CXCL10, and CXCL9 were analyzed in serum samples obtained from a
Data are expressed as mean SD. Mann–WhitneyU test and Student’s
groups (

P<0.05,

P<0.01,

P<0.01, ns¼not significant). BD¼
4 | www.md-journal.comMore specifically, IL-8 is known to be involved in the
neutrophils activation as well as in leukocytes migration. In
addition, it promotes the differentiation of mononuclear to
granulocytic infiltration and the adhesion of peripheral blood
leukocytes to endothelial cells. Several studies reported elev-
ated IL-8 levels in serum from BD patients compared to HC, but
discordant results were obtained when a relation to disease
activity was investigated. In particular, IL-8 significantly cor-
relate to specific BD clinical characteristic such as oral ulcers,
skin lesions, and ocular involvement due to its role in the
inflammatory response and its capability to attract polymorpho-
nuclear cells into the lesions.11–16 However, these findings are
disease, HC¼ healthy controls, SAA¼ serum amyloid A. P< 0.05,
oup.controversial.15
IL-18 is a proinflammatory cytokines over-expressed in
BD.24 It is principally produced by APCs and is involved in Th1
and HC. Circulating level of IL-8, IL-18, IL-6, IFN-a2a, CXCL11,
ctive-BD (n¼37), inactive-BD (n¼41), and HC (n¼32) subjects.
t-test were carried out to check for statistical significance between
Behcet’s disease, HC¼healthy controls, SD¼ standard deviation.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 3. Serum cytokines levels in low-SAA BD, high-SAA BD patients, and HC. Circulating level of IL-8, IL-18, IL-6, IFN-a2a, CXCL11,
CXCL10, and CXCL9 were analyzed in serum samples obtained from BD patients with SAA serum levels 20 mg/L (low-SAA, n¼20),
as m
.05
Medicine  Volume 94, Number 42, October 2015 Cytokines and Behcet’s Diseasepolarized immune response as well as in IL-6, IFN-a, and IL-12
production.6 Moreover, IL-18 seems to enhance chemokine
productions, especially CXC, and induce INF-g release by
NK cells, suggesting a role also in innate responses. Although
serum IL-18 levels have been observed to be not significantly
different between active and inactive BD patients,25 we found
that IL-18 correlates with disease activity. Notably, the detec-
tion of increased levels of IL-18 in patients with inactive disease
might be explained by a smouldering subclinical inflammation
during intercritical periods.
Interestingly, in our study serum IL-6 and IFN-a levels
were significantly higher exclusively in patients with active
disease compared to HC. IFN-a is a cytokine involved in BD
pathogenesis presenting pleiotropic effects. Especially, IFN-a
may significantly increase IFN-g levels in memory CD4þ T
cells and inhibit Th1 and Th17 cells.26 Several studies suggest
that IFN-a promotes a regulatory Th1 response causing anti-
inflammatory effects mainly through an increase in soluble
cytokine receptors, cytokine antagonists, and soluble adhesion
molecules.27–29 Few data are available concerning IFN-a levels
in BD. Ko¨tter et al30 observed increased IFN-a serum levels in a
group of BD patients with ocular involvement. More recently, it
has been suggested that high serum IFN-a levels in BD patients
might be due to increased frequency and activation of IFN-aþ
plasmacytoid dendritic cells (pDC) resulting in Th1 type
immune response.27
With regard to IL-6, it is mainly produced by activated
macrophages and monocytes, but is also released by other cell
types such as APCs and lymphocytes. IL-6, known to be
>20 mg/L (high-SAA, n¼50), and HC (n¼32). Data are expressed
out to check for statistical significance between groups (

P<0
controls, SAA¼ serum amyloid-A.associated to monocyte differentiation and CD4þ T cells
differentiation into Th17 cells, is linked to BD activity.6,31,32
In addition, it also seems to play a critical role in BD patients
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.presenting with central nervous system involvement,33 albeit it
might have a protective role on mucocutaneous BD features.34
Since we recently demonstrated a correlation between
increased SAA serum levels and various typical BD clinical
manifestations;20 in the present, study we also looked for
possible different cytokine patterns in patients with low and
high SAA serum levels.
Noteworthy, we observed that BD patients with SAA
higher than 20 mg/L showed intriguing characteristics in terms
of proinflammatory cytokines serum levels. In particular, IL-18,
IFN-a2a, and IL-6 were higher in patients with at least 20 mg/L
SAA levels than in HC, while IL-8 and CXCL9 levels were
higher in patients with SAA >20 mg/L than in patients with
SAA 20 mg/L and in HC. Although SAA is mainly produced
in the liver by proinflammatory stimuli such as IL-6, IL-1, and
TNFa,35 also other cell types are known to produce SAA-
including activated endothelial cells and monocytes/macro-
phages.36,37 Moreover, monocytes and monocytes derived
macrophages have been reported to produce proinflammatory
cytokines after SAA stimulation.38 Indeed, it has been recently
demonstrated that SAA may stimulate the release of mature IL-
1b from neutrophils, macrophages, and fibroblasts through
inflammasome activation.39–41 Interestingly, the release of
IL-8 as well as TNF-a from SAA-stimulated neutrophils was
also reported.42 In addition, it has been observed that SAA
induces neutrophil transmigration, monocyte migration, and
peripheral blood mononuclear cells adhesion in an IL-8 and
monocyte chemoattractant protein-1 dependent manner.43 The
main limitations of our study are represented by the sample size
ean SD. Mann–Whitney U test and Student’s t-test were carried
,

P<0.01,

P<0.01). BD¼Behcet’s disease, HC¼healthythat did not allow us to compare data according to specific organ
involvement, and the absence of a disease control group, that
could add more information regarding the disease specificity of
www.md-journal.com | 5
the alterations observed. Moreover, at the time of samples
collection, all of the patients were already taking corticosteroids
and immunosuppressive agents, which might have affected
cytokines serum levels.
In conclusion, our findings corroborate that BD patients
exhibit elevated levels of specific inflammatory mediators,
especially during active disease periods and in patients with
increased SAA serum levels. Notably the increased levels of
proinflammatory cytokines found in our study show that the
immune response in BD is skewed toward a Th1 pathway.
However, no obvious differences in cytokine profile between
active and inactive-BD patients were found. This lack of
differences may be due to various grounds such as different
subsets of patients, admission criteria, besides the treatment
regimens. For the above reason it is difficult to attribute an
actual pathogenic role for each cytokine as regards the cyto-
kines profile between active and inactive patients. Together
with all the results from studies aimed at exploring, the patho-
genetic role of cytokines in BD, these findings, may certainly
contribute to improve our knowledge regarding specific target
for novel therapies or for a different and more specific use of
biologic drug currently available.44–48 However, although our
suggestion of a possible SAA role in the induction of BD
inflammatory manifestations is intriguing, further studies are
needed both to better understand this pathogenetic perspective
and to investigate the possible role of SAA inhibition in such
patients. In order to confirm the results of our proof of concept
study on the role of SAA, cytokines profile, and disease activity,
a validation study on a larger cohort is ongoing.
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